- Home
- RAND vs ALGS Comparison
RAND vs ALGS Comparison
Compare RAND & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- ALGS
- Stock Information
- Founded
- RAND 1969
- ALGS 2018
- Country
- RAND United States
- ALGS United States
- Employees
- RAND N/A
- ALGS N/A
- Industry
- RAND Finance: Consumer Services
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- ALGS Health Care
- Exchange
- RAND Nasdaq
- ALGS Nasdaq
- Market Cap
- RAND 54.4M
- ALGS 53.0M
- IPO Year
- RAND N/A
- ALGS 2020
- Fundamental
- Price
- RAND $16.13
- ALGS $10.55
- Analyst Decision
- RAND
- ALGS Strong Buy
- Analyst Count
- RAND 0
- ALGS 2
- Target Price
- RAND N/A
- ALGS $60.00
- AVG Volume (30 Days)
- RAND 5.0K
- ALGS 79.6K
- Earning Date
- RAND 08-04-2025
- ALGS 08-06-2025
- Dividend Yield
- RAND 10.35%
- ALGS N/A
- EPS Growth
- RAND N/A
- ALGS N/A
- EPS
- RAND N/A
- ALGS N/A
- Revenue
- RAND $7,966,118.00
- ALGS $3,174,000.00
- Revenue This Year
- RAND N/A
- ALGS N/A
- Revenue Next Year
- RAND N/A
- ALGS $28.79
- P/E Ratio
- RAND N/A
- ALGS N/A
- Revenue Growth
- RAND 1.16
- ALGS N/A
- 52 Week Low
- RAND $13.82
- ALGS $3.76
- 52 Week High
- RAND $31.89
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- RAND 46.94
- ALGS 65.47
- Support Level
- RAND $15.17
- ALGS $8.39
- Resistance Level
- RAND $16.20
- ALGS $11.70
- Average True Range (ATR)
- RAND 0.91
- ALGS 0.90
- MACD
- RAND 0.06
- ALGS 0.27
- Stochastic Oscillator
- RAND 71.52
- ALGS 73.83
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.